Cart
sales@molnova.com
NS-102
CAS No. 136623-01-3
NS-102( —— )
Catalog No. M35069 CAS No. 136623-01-3
NS-102 is a glutamate receptor and NMDA receptor antagonist that inhibits erythrocyanine (GluK2), which reduces glur6 receptor-mediated currents, and inhibits specific binding to the glur6 receptor.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 5MG | 376 | In Stock |
|
| 10MG | 629 | In Stock |
|
| 25MG | 1036 | In Stock |
|
| 50MG | 1367 | In Stock |
|
| 100MG | 1841 | In Stock |
|
| 200MG | Get Quote | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameNS-102
-
NoteResearch use only, not for human use.
-
Brief DescriptionNS-102 is a glutamate receptor and NMDA receptor antagonist that inhibits erythrocyanine (GluK2), which reduces glur6 receptor-mediated currents, and inhibits specific binding to the glur6 receptor.
-
DescriptionNS-102 is a selective kainate (GluK2) receptor antagonist. NS-102 is a potent GluR6/7 receptor antagonist.
-
In Vitro——
-
In Vivo——
-
Synonyms——
-
PathwayNeuroscience
-
TargetGluR
-
RecptorGluR | NMDAR
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number136623-01-3
-
Formula Weight261.23
-
Molecular FormulaC12H11N3O4
-
Purity>98% (HPLC)
-
SolubilityIn Vitro:?DMSO : 4 mg/mL (15.31 mM; Ultrasonic (<60°C)
-
SMILESO\N=C1/C(=O)Nc2c1cc(c1CCCCc21)[N+]([O-])=O
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Selva Baltan Tekk?k, et al. Excitotoxic mechanisms of ischemic injury in myelinated white matter. J Cereb Blood Flow Metab. 2007 Sep;27(9):1540-52.?
molnova catalog
related products
-
VU0422288
VU0422288 (ML396) is a potent orthosteric modulator of type III mGlu receptors (mGlus).VU0422288 shows inhibition of mGluR4, mGluR7, and mGluR8 in a calcium mobilization assay.
-
Piracetam
Piracetam is a cyclic derivative of the neurotransmitter gamma-aminobutyric acid (GABA), used in treatment of a wide range of cognitive disorders.
-
NPS2390
NPS2390 is a first generation quinoxaline derivative that acts as a noncompetitive antagonist of mGluR1 and mGluR5 (IC50 of 5.2 and 82 nM, respectively).
